Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Theravance Biopharma, Inc. (TBPH)  
$9.01 0.19 (2.15%) as of 4:30 Wed 3/27


Download
   
Exchange: N/A
Security Type: N/A
Shares Out: 63,980,000
Market Cap: 576.46(M)
Last Volume: 0 Avg Vol: 0
52 Week Range: $8.22 - $11.92
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:

   

Rankings:

     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  245
Guru Rank Value     : 4.8
Guru Occurances    : 2

 

            6 Months   1 Year   2 Year  
 
Company Profile   Theravance Biopharma is a biopharmaceutical company primarily focused on the discovery, development and commercialization of respiratory medicine medicines. Co.'s program include: YUPELRI™ (revefenacin) inhalation solution, nebulized long-acting muscarinic antagonist for the maintenance treatment of chronic obstructive pulmonary disease; and Lung-selective, Nebulized Pan-Janus Kinase (JAK) Inhibitor (Nezulcitinib), a lung-selective, nebulized JAK inhibitor, in clinical development for the potential treatment of hospitalized patients with acute lung injury caused by Coronavirus Disease 2019.


 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 1,254 7,596 25,286 172,089
Total Sell Value $10,922 $72,880 $259,072 $1,835,193
Total People Sold 1 2 2 4
Total Sell Transactions 1 4 12 21
End Date 2023-12-28 2023-09-26 2023-03-28 2022-03-28

   
Records found: 524
  Page 1 of 21  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Winningham Rick E CHIEF EXECUTIVE OFFICER   •       •      –    2024-03-15 4 GA $0.00 $0 I/I 3,900 3,900     -
   Winningham Rick E CHIEF EXECUTIVE OFFICER   •       •      –    2024-03-15 4 GD $0.00 $0 D/D 10,900 1,550,573     -
   Winningham Rick E CHIEF EXECUTIVE OFFICER   •       •      –    2024-03-15 4 A $8.64 $23,363 D/D 2,704 1,561,473     -
   Farnum Rhonda SVP, COMM & MEDICAL AFFAIRS   •       –      –    2024-02-22 4 AS $8.71 $10,922 D/D (1,254) 311,733 3%     
   Farnum Rhonda SVP, COMM & MEDICAL AFFAIRS   •       –      –    2024-02-20 4 D $8.92 $162,513 D/D (18,219) 312,987     -
   Winningham Rick E CHIEF EXECUTIVE OFFICER   •       •      –    2024-02-20 4 D $8.92 $331,788 D/D (37,196) 1,558,769     -
   Graham Richard A SVP, RESEARCH & DEVELOPMENT   •       –      –    2024-02-20 4 D $8.92 $172,102 D/D (19,294) 314,915     -
   Sawaf Aziz SVP & CHIEF FINANCIAL OFFICER   •       –      –    2024-02-20 4 D $8.92 $151,961 D/D (17,036) 238,636     -
   Miller Aine SVP, DEV & HEAD OF IRE OFFICE   •       –      –    2024-02-20 4 D $8.92 $105,095 D/D (11,782) 133,534     -
   Grimaud Brett A. SVP, GEN COUNSEL AND SECRETARY   •       –      –    2024-02-20 4 D $8.92 $156,947 D/D (17,595) 260,684     -
   Miller Aine SVP, Dev & Head of IRE Office   •       –      –    2024-02-06 3 IO $0.00 $0 D/D 0 145,316     -
   Grant Jeremy T   –       •      –    2023-12-21 4 A $0.00 $0 D/D 11,768 11,768     -
   Farnum Rhonda SVP, COMM & MEDICAL AFFAIRS   •       –      –    2023-11-21 4 AS $10.29 $14,180 D/D (1,378) 331,206 -13%     
   Grimaud Brett A. SVP, GEN COUNSEL AND SECRETARY   •       –      –    2023-11-20 4 D $10.37 $76,354 D/D (7,363) 278,279     -
   Sawaf Aziz SVP & CHIEF FINANCIAL OFFICER   •       –      –    2023-11-20 4 D $10.37 $64,159 D/D (6,187) 255,672     -
   Graham Richard A SVP, RESEARCH & DEVELOPMENT   •       –      –    2023-11-20 4 D $10.37 $130,973 D/D (12,630) 334,209     -
   Winningham Rick E CHIEF EXECUTIVE OFFICER   •       •      –    2023-11-20 4 D $10.37 $163,887 D/D (15,804) 1,595,965     -
   Farnum Rhonda SVP, COMM & MEDICAL AFFAIRS   •       –      –    2023-11-20 4 D $10.37 $82,773 D/D (7,982) 332,584     -
   Graham Richard A SVP, RESEARCH & DEVELOPMENT   •       –      –    2023-11-14 4 AS $10.22 $25,366 D/D (2,482) 346,839 -13%     
   Graham Richard A SVP, RESEARCH & DEVELOPMENT   •       –      –    2023-10-30 4 A $0.00 $0 D/D 15,000 349,321     -
   Graham Richard A SVP, RESEARCH & DEVELOPMENT   •       –      –    2023-10-16 4 AS $9.03 $22,412 D/D (2,482) 334,321 2%     
   Graham Richard A SVP, RESEARCH & DEVELOPMENT   •       –      –    2023-09-14 4 AS $9.89 $24,547 D/D (2,482) 336,803 1%     
   Farnum Rhonda SVP, COMM & MEDICAL AFFAIRS   •       –      –    2023-08-22 4 AS $9.47 $17,112 D/D (1,807) 340,566 19%     
   Graham Richard A SVP, RESEARCH & DEVELOPMENT   •       –      –    2023-08-20 4 D $9.70 $101,472 D/D (10,461) 339,285     -
   Farnum Rhonda SVP, COMM & MEDICAL AFFAIRS   •       –      –    2023-08-20 4 D $9.70 $101,462 D/D (10,460) 342,373     -

  524 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 21
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed